Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 3/20 | 0.53 |
| ▸ | TLR4 | O00206 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.33 |
| ▸ | STAT3 | P40763 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13998183 | 0.88 | PTPN1 (0.49) | PTPN1TLR4POLBCTDSP1STAT3 | |
| SCHEMBL14010919 | 0.82 | PTPN1 (0.46) | PTPN1TLR4POLBCTDSP1STAT3 | |
| SCHEMBL13998037 | 0.78 | PTPN1 (0.43) | PTPN1TLR4POLBCTDSP1STAT3 | |
| Shanzhiside Methyl Ester SCHEMBL12207355 | 0.75 | POLB (0.62) | POLBCTDSP1STAT3MEN1KMT2A | |
| Shanzhiside Methyl Ester SCHEMBL29965826 | 0.75 | POLB (0.62) | POLBCTDSP1STAT3MEN1KMT2A | |
| Shanzhiside Methyl Ester SCHEMBL28007134 | 0.75 | POLB (0.62) | POLBCTDSP1STAT3MEN1KMT2A | |
| SCHEMBL28252239 | 0.73 | PTPN1 (0.41) | PTPN1TLR4POLBCTDSP1NPC1 | |
| SCHEMBL13998041 | 0.73 | PTPN1 (0.39) | PTPN1TLR4POLBCTDSP1 | |
| SCHEMBL10042261 | 0.72 | PTPN1 (0.33) | PTPN1 | |
| SCHEMBL13998090 | 0.72 | PTPN1 (0.41) | PTPN1TLR4POLBCTDSP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080319042-A1 | Compositions and methods for treatment of liver disease | CALECO PHARMA CORP. | 2008-12-25 | — | — | US | disclosed |
| US-20080319042-A1 | Compositions and methods for treatment of liver disease | CALECO PHARMA CORP. | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319042-A1 | Compositions and methods for treatment of liver disease | HCCS, HAVCR2, PYGL | PTPN1 3880/4885TLR4 2654/4885POLB 712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.